{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-003387","form_type":"8-K","ticker":"CELU","cik":"0001752828","company_name":"Celularity Inc","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.398474+00:00","generated_at":"2026-06-07T01:36:28.131607+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Celularity expects Q4 biomaterial/biobanking net sales up 176–193% YoY, full year up 23–27%","bullets":["Q4 2023 net sales expected $11.4M–$12.1M, up 176–193% vs Q4 2022.","Full year 2023 net sales expected $22.06M–$22.76M, up 23–27% vs FY 2022.","Excludes other revenue, including the Regeneron research collaboration agreement.","Company plans to provide 2024 revenue guidance soon; aims to boost cash flow from commercial products.","Actual Q4 and FY 2023 net sales and total revenue to be announced later in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-003387","json":"https://secwatch.observer/filing/0000950170-24-003387.json","markdown":"https://secwatch.observer/filing/0000950170-24-003387.md","text":"https://secwatch.observer/filing/0000950170-24-003387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1752828/000095017024003387/0000950170-24-003387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1752828/000095017024003387/celu-20240103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:36:28.131607+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43b9ff5e70eb59a76cc4ad2829ea1dbefd6f417f","claim":"Celularity Inc reported fourth quarter 2023 results: revenue expected net sales ... to be in the range of $11.4 million to $12.1 million. Guidance reaffirmed.","evidence_excerpt":"Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023 Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year 2023 reflecting triple-digit increases compared to the fourth quarter 2022 and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1752828/000095017024003387/0000950170-24-003387-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2023"},{"label":"Revenue","value":"expected net sales ... to be in the range of $11.4 million to $12.1 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"995499b3f3647c0b26d52b2a1a7a3b9bc4b4bb80","claim":"Celularity Inc reported full year 2023 results: revenue expected net sales ... to be in the range of $22.06 million to $22.76 million. Guidance reaffirmed.","evidence_excerpt":"Year 2023 Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year 2023 reflecting triple-digit increases compared to the fourth quarter 2022 and full year 2022, respectively. These numbers do not include","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1752828/000095017024003387/0000950170-24-003387-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"expected net sales ... to be in the range of $22.06 million to $22.76 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}